Paul Robbins, MD
Psychiatry · Summerville, SCNPI 1780757237
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 64.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $4,917 and has fallen 87.1% since, to $634 in 2025. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $79.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Sunovion Pharmaceuticals Inc.$557
- AbbVie$473
- Neurocrine Biosciences, Inc.$405
- Teva Pharmaceuticals USA, Inc.$295
- E.r. Squibb & Sons, L.L.C.$251
- plus $490 from 7 others
Across 168 payments — averaging $7857.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$644K
- AbbVie$222K
- Janssen Research & Development, LLC$101K
- Arbor Pharmaceuticals, Inc.$99K
- Supernus Pharmaceuticals, Inc.$80K
- Acadia Pharmaceuticals Inc$56K
- plus $118K from 4 others
What the payments were for
- Speaking & faculty fees$2,25033%
- Travel & lodging$95714%
- Food & beverage$3,70954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 25 | $4,444 |
| Sunovion Pharmaceuticals Inc. | 14 | $557 |
| AbbVie(2 entities) | 14 | $473 |
| Neurocrine Biosciences, Inc. | 7 | $405 |
| Teva Pharmaceuticals USA, Inc. | 5 | $295 |
| E.r. Squibb & Sons, L.L.C. | 3 | $251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $130 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $97 |
| Alkermes, Inc. | 5 | $88 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $49 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$3,799
- LATUDA$353
- VRAYLAR$342
- INGREZZA$256
- COBENFY$226
- AUSTEDO$125
- INVEGA SUSTENNA$122
- INVEGA TRINZA$122
- Austedo XR$120
How this compares
$6,916 in reported general payments places this provider in the 90th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 23 | $209,164 |
| Invega SustennaPaliperidone Palmitate | 70 | $205,013 |
| UzedyRisperidone | 22 | $46,277 |
| Abilify MaintenaAripiprazole | 16 | $46,221 |
| AristadaAripiprazole Lauroxil | 12 | $38,269 |
| RexultiBrexpiprazole | 13 | $22,136 |
| Aripiprazole | 61 | $5,387 |
| Paliperidone ErPaliperidone | 25 | $2,850 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $800 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $710 |
| Ziprasidone Hcl | 28 | $550 |
| Lurasidone Hcl | 14 | $465 |
| Quetiapine Fumarate | 60 | $413 |
| Alprazolam ErAlprazolam | 11 | $397 |
| Benztropine Mesylate | 32 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $4,444 | $414,17793 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $51 | $68,35729 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $295 | $46,27722 claims |
| Alkermes, Inc.Aristada | $88 | $38,26912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Summerville
- Brittany AlbrightMount Pleasant$691K
- Veronica RidpathFlorence$364K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Jeffrey StephensGreenville$195K
- Robert RichardsGreenville$142K
- Nikunjkumar ModiFlorence$133K
- Jacobo MintzerCharleston$132K
- Murray HonickMyrtle Beach$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.